| Name | Title | Contact Details |
|---|---|---|
Jay Hawkinson |
CIO / Chief Architect | Profile |
Your Single Source for all IT & Cybersecurity Solutions NuView Advisors is a group of vCIO/vCTO/vCISO and IT professionals with decades working with organizations of all sizes to standardize IT and Cybersecurity service delivery to the highest standards. Working with NuView is a force multiplier for IT and Cybersecurity departments to focus on higher value strategic activities, streamlining services across existing organizations and helping startups quickly build their IT services for security and scale.
SMSI is a small business providing management and technical/engineering services to the DOE/NNSA, national laboratories, and industrial clients. Our work with nuclear facility operations and safety has set the standard for excellence. We are the resource for highly technical engineering and nuclear safety basis development, review, and implementation at the national laboratories. SMSI has a demonstrated record of success providing superior people developing and implementing innovative solutions, delivering projects on time and within budget. We build productive relationships by being highly responsive to our customers. Operations began in 2000 with headquarters in Albuquerque, NM, and currently operating offices in Los Alamos, NM and Oak Ridge, TN.
HealthSherpas mission is to help every American feel the comfort and security of having health coverage. HealthSherpa is the largest and fastest-growing individual health coverage exchange in the United States, simplifying access to ACA and Medicare health plans from both federal and state marketplaces. Our secure, integrated technology platform empowers insurance agents, agencies, and carriers to quickly and accurately serve and support individuals as they select and use quality, affordable health plans.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.